Molecular Mechanisms: Hypoxia-HIF-Adenosine-Iron Axis and RLS Gene Function

Medical disclaimer: this is a research synthesis, not medical advice. RLS is a chronic neurological condition; nothing here claims a "cure." Dopamine-agonist and alpha-2-delta-ligand tapering must only be done under physician supervision - never stop abruptly. See docs/00_MASTER_PLAN.md Section 2.

This synthesis targets the two mechanism families flagged as thin for the mechanistic brain simulation (deliverable R2-A): (a) the hypoxia/HIF-adenosine-iron axis linking peripheral leg hypoxia, brain iron deficiency, and adenosine hypofunction, and (b) the functional biology (not just GWAS association) of the five anchor RLS genes - BTBD9, MEIS1, PTPRD, MAP2K5/SKOR1, and TOX3. It draws on 20 newly written study notes plus 25 notes already in this knowledge base that a prior sweep had tagged with this exact topic but never synthesized, most heavily the A11 diencephalospinal 6-OHDA/iron-deprivation rodent-model literature. Every claim below cites a study note (filename) or PMID.

What is established (grade A/B)

• High residential altitude is an independent, population-level risk factor for RLS: prevalence rose from 2.5% at 400 m to 12.2% (1900-2000 m) and 11.8% (3200 m) in a 1,689-person Indian Himalayan cohort, and altitude remained an independent predictor (adjusted OR 5.4, 95% CI 2.8-10.4) after controlling for peripheral neuropathy, COPD, varicose veins, anemia, sex, and parity (grade B; 2017-gupta-high-altitude-rls-prevalence.md, PMID 28619185).
• Low peripheral iron stores predict periodic leg movements at a population level, independent of the tested RLS-risk genotypes: in the 801-person Wisconsin Sleep Cohort, ferritin <=50 ng/mL was associated with PLMI>=15/h (OR 1.55, p=0.020), with a dose-response slope of 0.0034 PLM/h per 1 ng/mL ferritin decrease (p=0.00447), after adjusting for BTBD9, TOX3, MEIS1, MAP2K5/SKOR1, and PTPRD polymorphisms (grade B; 2015-li-ferritin-plm-wisconsin-cohort.md, PMID 26498245).
• Peripheral leg-specific hypoxia occurs during enforced immobility in RLS (transcutaneous pO2 5.54 vs 7.19 kPa in controls, p<0.01; larger chest-to-foot O2 gradient correlating with severity, rho=0.692) and is partially reversed by pramipexole (5.54 to 6.65 kPa, p<0.05) (grade B; pre-existing 2014-salminen-peripheral-hypoxia-rls.md, PMID 24789861).

Emerging C

• Plasma HIF-1alpha is markedly elevated in RLS (median 3846 pg/mL) versus both Parkinson's disease (1744 pg/mL) and controls (1157 pg/mL), tracking with a coordinated arginine-citrulline-ornithine metabolomic shift, in a small (n=13 RLS) cross-sectional cohort with a same-day median ferritin of only 12 ng/mL (2026-dumur-hif1a-arginine-metabolomics.md, PMID 42512854).
• CSF proteomics in early-onset RLS shows a protein profile (elevated cystatin C +11.3-fold, beta-hemoglobin +4.5-fold, prostaglandin D2 synthase, vitamin D-binding protein; reduced apolipoprotein A1, alpha-1-acid glycoprotein) the authors interpret as consistent with HIF-pathway activation and altered dopaminergic systems (2013-patton-csf-proteomics-rls.md, PMID 23758918), consistent with the autopsy/microvessel HIF-1alpha/HIF-2alpha/VEGF/erythropoietin findings already in the KB (pre-existing 2011-patton-hif-pathway-activation.md, PMID 21985026).
• Leg-muscle capillary geometry is structurally remodeled in RLS: significantly higher capillary tortuosity (LC/PF index, p=0.01) and lower predicted VO2max (p=0.01) on tibialis anterior biopsy (2007-larsson-skeletal-muscle-capillary-rls.md, PMID 17622717), and thermovascular/laser-Doppler testing significantly discriminates RLS patients from controls (p<0.001), with more spatially uniform (less variable) foot temperature during a heat challenge (2013-anderson-laser-doppler-microvascular-rls.md, PMID 23397977) - converging with diurnal leg-blood-flow blunting already in the KB (pre-existing 2014-oskarsson-diurnal-leg-blood-flow.md, PMID 24521165).
• TOX3 shows a genuine functional developmental role beyond GWAS association: it is a Nestin-promoter-binding, Notch-cooperating driver of neural progenitor identity and migration in the embryonic mouse brain (2016-sahu-tox3-neural-progenitor-identity.md, PMID 27080130), and separately a CREB/CBP-binding, calcium-dependent transcriptional regulator required for calcium-induced c-fos expression in neurons (2009-yuan-tox3-calcium-transcription-neurons.md, PMID 19196971); clinically, a TOX3 variant shows opposite-direction associations with RLS (protective, OR 0.70) versus a nominal PD risk signal (OR 1.62, not surviving correction) (2018-mohtashami-tox3-rls-parkinsons-opposite.md, PMID 29404899), and a different TOX3 variant is specifically linked to a painful-RLS subphenotype (pre-existing 2019-karroum-tox3-painful-rls-variant.md, PMID 31706190, OR 1.67).
• PTPRD has a demonstrated causal role in sensory-neuron (dorsal root ganglion) pain signaling: it is expressed exclusively in DRG neurons, rises progressively after nerve injury tracking hypersensitivity onset, and its knockdown (75% mRNA / 47% protein reduction) or pharmacological inhibition significantly reduces neuropathic pain via a STING-type-I-interferon pathway (2022-sun-ptprd-neuropathic-pain-drg.md, PMID 35493326); a related mechanistic line shows PTPRD (PTPdelta) enables Sema3A-guided dendritic/axonal growth of both DRG and cortical neurons via Fyn-kinase dephosphorylation (2017-nakamura-ptprd-sema3a-dendrite-growth.md, PMID 28637841), and its behavioral function depends more on the alternative-splicing pattern of a 4-amino-acid microexon than on total protein level (2026-imai-ptprd-microexon-splicing-behavior.md, PMID 41950098).
• BTBD9 controls striatal/spinal dopamine-receptor biology through a circadian-dependent, transcription/translation-uncoupling mechanism (D2 receptor mRNA up but protein down at midday, with dynamin-1-mediated internalization implicated) and abolishes the spinal D1-receptor-agonist response, conserved down to a C. elegans D2-like-receptor (dop-3) interaction (2020-lyu-btbd9-dopamine-receptor-mechanism.md, PMID 32468214); it independently governs cerebellar Purkinje-cell excitability (increased non-tonic firing, p=0.002; increased tonic-cell firing frequency and intrinsic excitability, p=0.04), and a Purkinje-cell-specific knockout alone reproduces rest-phase motor restlessness (2020-lyu-btbd9-cerebellum-sleep-behavior.md, PMID 32446853) - complementing the pre-existing cortical (2019-lyu-btbd9-cerebral-cortex-corticostriatal.md, PMID 31715135) and striatal medium-spiny-neuron (2019-lyu-btbd9-striatum-medium-spiny.md, PMID 31444227) site-of-action data already in the KB.
• A circulating serum factor common to both idiopathic and dialysis-associated (secondary) RLS increases leg-muscle activity during sleep specifically in Btbd9-mutant mice (not wild-type), and this is reversed by the dopamine agonist rotigotine - direct evidence of genotype-by-environment interaction (2019-muramatsu-btbd9-rotigotine-dialysis-sera.md, PMID 31704978).

Contested or negative findings

• Occupational cabin-altitude hypoxia in aircrew was not associated with increased RLS risk (6.7% vs 7.9% in non-aircrew controls, not significant), in contrast to the strong residential-altitude signal above - suggesting chronic/permanent hypoxic exposure (or a confounded healthy-flyer population) behaves differently from intermittent occupational exposure (pre-existing 2019-duz-aircrew-altitude-negative.md, PMID 31666154).
• A formal chronic-mountain-sickness (CMS) diagnosis was not independently associated with RLS in multivariate analysis at high altitude; only reduced oxygen saturation itself, poor sleep quality, and CMS-severity score were independent correlates - meaning the hypoxia-RLS link at altitude is not simply mediated through the clinical CMS syndrome (pre-existing 2015-vizcarra-escobar-mountain-sickness-oxygen.md, PMID 26026624).
• BTBD9 and MEIS1 - the two strongest RLS GWAS genes - do not directly regulate one another at the molecular level: Btbd9 deficiency did not alter Meis1 protein, and Meis1 haploinsufficiency did not alter Btbd9 transcription in mice, even though the two genes interact behaviorally (partial phenotype rescue/acceleration) in C. elegans and mouse double mutants (2020-lyu-btbd9-meis1-noninteraction.md, PMID 34268480).
• A 2016 review found no known RLS risk gene maps directly onto classical iron-regulatory pathways, and the common HFE C282Y hemochromatosis mutation shows no protective effect, even while the same review flags hypoxia-pathway protein activation in RLS brain tissue as a consistent, unexplained finding (pre-existing 2016-connor-iron-genetics-hypoxia-review.md, PMID 28057495) - a tension this synthesis' new gene-function notes partially resolve by showing BTBD9, MEIS1, and SKOR1 each converge on iron-handling genes (IRP2, ferritin, DMT1, HMOX1) despite not being classical "iron pathway" genes by annotation.
• CSF H-ferritin was measured but did not reach statistical significance between early-onset RLS and controls in the same small proteomic study that found significant differences in cystatin C and other proteins, illustrating that CSF iron-protein differences are not always detectable even when downstream (HIF-consistent) signaling differences are (2013-patton-csf-proteomics-rls.md, PMID 23758918).

Mechanistic picture in 5 bullet points

1. Functional (not just anatomic) iron scarcity plausibly triggers a HIF-response cascade without true tissue hypoxia. Iron is a required cofactor for the prolyl-hydroxylases that normally degrade HIF-1alpha/HIF-2alpha; cellular iron deficiency can therefore activate the same transcriptional program as hypoxia even at normal oxygen tension (pre-existing 2011-patton-hif-pathway-activation.md; mechanistic map in 2017-xu-hif-iron-metabolism-review.md), and this HIF activation is now also documented in blood (2026-dumur-hif1a-arginine-metabolomics.md) and CSF-proteomic (2013-patton-csf-proteomics-rls.md) compartments in living RLS patients, not just autopsy tissue.
2. A parallel, partly independent peripheral-hypoxia axis operates in the legs themselves. Reduced transcutaneous leg pO2 (pre-existing 2014-salminen-peripheral-hypoxia-rls.md), structurally remodeled/tortuous leg-muscle capillaries with reduced aerobic capacity (2007-larsson-skeletal-muscle-capillary-rls.md), impaired microvascular/thermovascular regulation (2013-anderson-laser-doppler-microvascular-rls.md), and blunted diurnal leg blood flow (pre-existing 2014-oskarsson-diurnal-leg-blood-flow.md) together describe a leg-tissue-oxygenation deficit whose causal direction relative to central iron/dopamine dysfunction remains unresolved (flagged explicitly in spinal-peripheral-plms.md).
3. BTBD9 acts through at least three independently sufficient anatomical sites, each producing rest-phase motor restlessness on its own: striatal medium spiny neurons (pre-existing), cerebral cortex (pre-existing), and cerebellar Purkinje cells (2020-lyu-btbd9-cerebellum-sleep-behavior.md) - via a circadian-gated dopamine-receptor transcription/translation uncoupling mechanism (2020-lyu-btbd9-dopamine-receptor-mechanism.md) that does not require any change in presynaptic substantia nigra dopamine-neuron firing.
4. MEIS1, SKOR1, and TOX3 converge functionally on iron handling and dorsal-horn/neurodevelopmental circuitry, not only on GWAS-defined loci: MEIS1 directly transactivates SKOR1 (pre-existing 2018-catoire-meis1-skor1-direct-regulation.md), and SKOR1 co-represses Lbx1 to specify dorsal-horn interneuron cell fate (pre-existing 2020-sarayloo-skor1-transcriptional-regulation.md) - the exact spinal sensory-processing structure implicated in RLS - while TOX3 independently drives neural-progenitor identity/migration (2016-sahu-tox3-neural-progenitor-identity.md) and calcium-dependent neuronal transcription (2009-yuan-tox3-calcium-transcription-neurons.md).
5. PTPRD's RLS-relevant function is most plausibly in dorsal-root-ganglion sensory-afferent signaling and growth, not central dopaminergic circuitry: it is DRG-neuron-specific, injury-inducible, and causally amplifies nociceptive signaling via STING-interferon signaling (2022-sun-ptprd-neuropathic-pain-drg.md), and separately enables Sema3A-directed sensory/cortical neurite outgrowth via Fyn kinase (2017-nakamura-ptprd-sema3a-dendrite-growth.md), with its behavioral output governed more by microexon splice-variant identity than raw expression level (2026-imai-ptprd-microexon-splicing-behavior.md).

Quantitative parameters for the simulation

Numbers the model can use now (with PMID and grade):

Parameters that do NOT exist in the literature (assumptions the simulation team must flag as such, not treat as data):

• No published absolute HIF-1alpha or HIF-2alpha concentration, half-life, or degradation/stabilization time constant specific to human brain tissue (thalamus, substantia nigra, spinal cord) in RLS - only qualitative immunoreactivity increases (autopsy) and one whole-blood ELISA value (2026-dumur-hif1a-arginine-metabolomics.md). Any brain-compartment HIF kinetic constant used in the simulation is an assumption, not a measured value.
• No dedicated leg-muscle or leg-skin near-infrared-spectroscopy (NIRS) tissue-oxygenation-index time course during exercise or immobility in RLS was found in this literature sweep (the one NIRS study in the KB, pre-existing 2016-byun-nirs-cerebral-hemodynamics-plms.md, measures cerebral, not leg, hemodynamics). A leg-NIRS-during-exercise quantitative curve for RLS is therefore an unmet data gap, not an assumption that can be calibrated from existing numbers.
• No human study quantifies a genotype-by-iron-status interaction effect size (e.g., BTBD9 or MEIS1 risk-allele dosage crossed with ferritin level) on any RLS phenotype; the only genotype-by-environment interaction data are animal (BTBD9 x dialysis-serum-factor, 2019-muramatsu-btbd9-rotigotine-dialysis-sera.md) or animal-genetic (BTBD9 x MEIS1 double-knockout, 2020-lyu-btbd9-meis1-noninteraction.md). Any human genotype x iron interaction term in the model is an assumption.
• No study reports a numeric fold-change for BTBD9's or MEIS1's effect on IRP2/ferritin/DMT1 expression in human (as opposed to Drosophila or C. elegans/mouse) tissue; the human data (pre-existing 2011-catoire-meis1-iron-homeostasis.md, 2019-sarayloo-meis1-mineral-absorption-pathway.md) are pathway-enrichment findings, not quantified fold-changes.
• No dose-response or pharmacokinetic data exist in this knowledge base for HIF-prolyl-hydroxylase inhibitors (the roxadustat/vadadustat drug class) or other direct HIF-pathway ligands tested in RLS or an RLS animal model; a brief ChEMBL/Open Targets check in this sweep confirmed BTBD9 (ENSG00000183826), MEIS1 (ENSG00000143995), and PTPRD (ENSG00000153707) are indexed targets but did not surface RLS-relevant tractability or ligand data worth citing as a claim, so this remains an open gap rather than a sourced parameter.
• No study measures adenosine A1-receptor density as an absolute number (receptors/mg tissue or Bmax) in RLS or brain-iron-deficient tissue; existing notes (pre-existing 2016-quiroz-adenosine-a1-receptor-downregulation.md, 2022-rodrigues-adenosine-receptor-stoichiometry.md) report direction (down) and terminal-specific ratio changes (A1:A2A selectively reduced in cortico-striatal, not thalamo-striatal, terminals) but not an absolute receptor-density number usable as a simulation constant.

Implications for a non-drug long-term plan for people currently on dopamine agonists or alpha-2-delta ligands

None of the following is a substitute for physician-supervised care. Dopamine-agonist tapering must be slow, physician-supervised, and never abrupt, because of augmentation and dopamine-agonist-withdrawal-syndrome (DAWS) risk (master plan Section 2/3).

• Because low ferritin predicts periodic leg movements on a graded, dose-response curve independent of genotype (2015-li-ferritin-plm-wisconsin-cohort.md), iron repletion to the AASM-guideline ferritin target remains a mechanistically well-supported, genotype-agnostic first lever during any physician-supervised taper - a patient's BTBD9/MEIS1/PTPRD/TOX3 genetic background does not appear to gate whether iron repletion is worth pursuing.
• The leg-specific (as opposed to purely central) hypoxia and microvascular findings (2007-larsson-skeletal-muscle-capillary-rls.md, 2013-anderson-laser-doppler-microvascular-rls.md, pre-existing 2014-salminen-peripheral-hypoxia-rls.md) support continuing to prioritize interventions that improve leg tissue perfusion - graded exercise, avoiding prolonged immobility, pneumatic compression, thermal/vascular therapies - as mechanistically plausible adjuncts during a taper, independent of dopaminergic dosing; this is reinforced by the animal literature showing treadmill exercise both treats and partially prevents A11-lesion-induced limb-movement increases (pre-existing 2016-esteves-exercise-protective-a11-lesion.md) and normalizes iron-deficiency-induced sleep impairment while raising dopamine-transporter and adenosine-A1-receptor expression (pre-existing 2026-franco-exercise-adenosine-dopamine-model.md).
• The discovery that BTBD9 acts through at least three independent anatomical sites (striatum, cortex, cerebellum) with a circadian-gated dopamine-receptor mechanism (2020-lyu-btbd9-dopamine-receptor-mechanism.md, 2020-lyu-btbd9-cerebellum-sleep-behavior.md) suggests that no single-target pharmacology (dopaminergic or otherwise) is likely to fully substitute for a taper without also addressing the evening/night-specific component of symptom generation - supporting the master plan's emphasis on circadian-timed, non-drug adjuncts (light, timed exercise, sleep-schedule regularity) alongside dose reduction.
• PTPRD's demonstrated role in sensory (DRG) hypersensitivity via a STING-interferon pathway (2022-sun-ptprd-neuropathic-pain-drg.md) identifies a mechanistically distinct, non-dopaminergic druggable node (PTPRD or STING inhibition) that is investigational, not currently available, but worth flagging in the simulation and protocol as a plausible future non-drug-class option for patients whose RLS has a strong painful/dysesthetic component - which the TOX3 painful-RLS subphenotype data (pre-existing 2019-karroum-tox3-painful-rls-variant.md) suggest is a genetically identifiable subgroup.
• Because occupational (cabin-altitude) hypoxia showed no RLS association while residential high-altitude living did (2019-duz-aircrew-altitude-negative.md vs 2017-gupta-high-altitude-rls-prevalence.md), patients and clinicians should not over-interpret short-duration hypoxic exposures (air travel) as an RLS trigger, while chronic residential hypoxia (e.g., patients relocating to altitude, or with chronic hypoxic lung/cardiac disease) may warrant closer symptom monitoring.

Open questions

• Is peripheral leg hypoxia/microvascular dysfunction a cause, a consequence, or a parallel epiphenomenon of central brain iron/dopamine dysfunction? This remains explicitly unresolved (flagged in spinal-peripheral-plms.md); none of the new hypoxia notes in this sweep establish direction, only association and partial dopaminergic reversibility.
• Does the HIF-1alpha elevation seen in blood (2026-dumur-hif1a-arginine-metabolomics.md) and CSF-consistent proteomics (2013-patton-csf-proteomics-rls.md) reflect the same brain-tissue process documented at autopsy (pre-existing 2011-patton-hif-pathway-activation.md), or a distinct peripheral/systemic signal? No study in this knowledge base measures HIF-1alpha simultaneously in blood, CSF, and brain tissue in the same RLS patients.
• Would a direct HIF-pathway-modulating drug (e.g., a prolyl-hydroxylase inhibitor) help or harm RLS, given HIF activation appears to be a marker of iron-deficiency-driven cellular stress rather than a confirmed independent driver of symptoms? No such trial or animal experiment exists in the literature surveyed.
• Does genotype at BTBD9, MEIS1, PTPRD, MAP2K5/SKOR1, or TOX3 modify the response to iron repletion, exercise, or dopamine-agonist tapering in humans? No human genotype-by-treatment-response study was found; only animal genotype-by-environment data exist (2019-muramatsu-btbd9-rotigotine-dialysis-sera.md).
• Given BTBD9's three independently sufficient anatomical sites of action, does human RLS actually involve all three circuits (striatal, cortical, cerebellar) simultaneously, or do different patients have a dominant circuit - and would that predict which non-drug therapy (e.g., cerebellar neuromodulation versus striatal-targeted approaches) works best for a given patient? Untested in humans.
• Does the PTPRD microexon-splicing mechanism (2026-imai-ptprd-microexon-splicing-behavior.md) apply to the common human RLS-associated PTPRD variant, and if so, does it shift splicing (as opposed to total expression)? Not yet tested.

Notes in this topic

New notes written for this sweep:

• 2026-dumur-hif1a-arginine-metabolomics.md - Plasma HIF-1alpha markedly elevated in RLS (and PD), tracking an arginine-citrulline-ornithine metabolic shift (PMID 42512854).
• 2013-patton-csf-proteomics-rls.md - CSF proteomic signature in early-onset RLS consistent with HIF-pathway activation and altered dopaminergic systems (PMID 23758918).
• 2017-dichtl-dopamine-iron-macrophages.md - Dopamine drives iron accumulation and Nrf2/HIF-1alpha oxidative-stress signaling in macrophages (PMID 29208364).
• 2017-xu-hif-iron-metabolism-review.md - Foundational review mapping HIF-1alpha/HIF-2alpha regulation of DMT1, ferroportin, Dcytb, TfR, hepcidin, and IRP1/IRP2 (PMID 29063108).
• 2013-anderson-irp1-hif2a-erythropoiesis.md - IRP1 (not IRP2) translationally represses HIF-2alpha, coordinating iron/oxygen sensing with erythropoiesis (PMID 23395174).
• 2018-xu-estrogen-hif-iron-astrocytes.md - Estrogen lowers brain-cell iron via HIF-1alpha-dependent (astrocyte) versus IRP1-dependent (neuron) mechanisms (PMID 30132882).
• 2007-larsson-skeletal-muscle-capillary-rls.md - Structurally remodeled, more tortuous leg-muscle capillaries and reduced VO2max in RLS (PMID 17622717).
• 2013-anderson-laser-doppler-microvascular-rls.md - Laser-Doppler/thermography demonstrates impaired leg microvascular regulation in RLS (PMID 23397977).
• 2015-li-ferritin-plm-wisconsin-cohort.md - Low ferritin predicts periodic leg movements on a graded dose-response curve, independent of genotype (PMID 26498245).
• 2020-lyu-btbd9-dopamine-receptor-mechanism.md - BTBD9 controls circadian-gated striatal D2-receptor transcription/translation uncoupling and spinal D1-response, conserved to C. elegans (PMID 32468214).
• 2020-lyu-btbd9-cerebellum-sleep-behavior.md - BTBD9 loss increases cerebellar Purkinje-cell excitability; Purkinje-specific knockout alone causes rest-phase motor restlessness (PMID 32446853).
• 2019-muramatsu-btbd9-rotigotine-dialysis-sera.md - A circulating serum factor common to idiopathic and renal RLS increases leg-muscle activity specifically in Btbd9-mutant mice (PMID 31704978).
• 2020-lyu-btbd9-meis1-noninteraction.md - Negative finding: BTBD9 and MEIS1 do not directly regulate each other's expression despite behavioral interaction (PMID 34268480).
• 2022-sun-ptprd-neuropathic-pain-drg.md - PTPRD in dorsal root ganglion sensory neurons causally amplifies neuropathic pain via STING-interferon signaling (PMID 35493326).
• 2017-nakamura-ptprd-sema3a-dendrite-growth.md - PTPRD/PTPdelta enables Sema3A-guided sensory and cortical neurite growth via Fyn kinase (PMID 28637841).
• 2023-ho-ptprd-knockout-behavior.md - Ptprd-knockout mice show impaired goal-directed behavior and female-specific sensorimotor-gating deficits (PMID 37205689).
• 2026-imai-ptprd-microexon-splicing-behavior.md - PTPRD's behavioral function depends on microexon splice-variant identity, not just total protein level (PMID 41950098).
• 2016-sahu-tox3-neural-progenitor-identity.md - TOX3 drives neural progenitor identity, proliferation, and migration via Nestin/Notch signaling (PMID 27080130).
• 2009-yuan-tox3-calcium-transcription-neurons.md - TOX3 is a CREB/CBP-binding, calcium-dependent transcriptional regulator in neurons (PMID 19196971).
• 2018-mohtashami-tox3-rls-parkinsons-opposite.md - A TOX3 variant shows opposite-direction associations with RLS versus Parkinson's disease risk (PMID 29404899).

Pre-existing notes (already in the knowledge base, tagged with this topic by an earlier sweep):

• 2000-ondo-a11-6ohda-lesion-model.md - Original A11 6-OHDA lesion rat model; 54% TH+ cell reduction, increased standing behavior reversed by pramipexole (PMID 10634257).
• 2008-pappas-a11-d2-autoreceptor-lack.md - A11 diencephalospinal neurons lack presynaptic D2-autoreceptor-mediated synthesis regulation (PMID 18462709).
• 2010-luo-pramipexole-long-term-a11-model.md - Combined iron-deprivation + A11-lesion mice show +186% moving time; pramipexole attenuates and partially restores spinal iron (PMID 21044864).
• 2011-lopes-a11-periodic-limb-movements-model.md - A11-lesioned rats show increased wakefulness and limb-movement frequency, reversed by pramipexole (PMID 22162115).
• 2012-deandrade-btbd9-hippocampal-plasticity.md - Btbd9 mutant mice show altered hippocampal synaptic plasticity and enhanced fear memory (PMID 22536397).
• 2012-freeman-drosophila-btbd9-iron-dopamine.md - Drosophila BTBD9 loss fragments sleep and alters dopamine; human BTBD9 controls iron via IRP2 (PMID 22658601).
• 2014-oskarsson-diurnal-leg-blood-flow.md - RLS patients lack the normal morning-evening leg blood-flow decline seen in controls (PMID 24521165).
• 2015-vizcarra-escobar-mountain-sickness-oxygen.md - Reduced oxygen saturation, not formal CMS diagnosis, independently associates with RLS at altitude (PMID 26026624).
• 2016-byun-nirs-cerebral-hemodynamics-plms.md - NIRS shows abnormal cerebral oxy/deoxyhemoglobin oscillation dynamics in RLS with PLMS (PMID 26754783).
• 2016-esteves-exercise-protective-a11-lesion.md - Treadmill exercise treats and partially prevents A11-lesion-induced limb movements (PMID 26923163).
• 2017-gupta-high-altitude-rls-prevalence.md - RLS prevalence rises sharply with residential altitude, independent of comorbidities (PMID 28619185).
• 2018-catoire-meis1-skor1-direct-regulation.md - MEIS1 directly transactivates SKOR1 by promoter binding, prioritizing SKOR1 in the MAP2K5/SKOR1 locus (PMID 30111810).
• 2019-duz-aircrew-altitude-negative.md - Negative: occupational cabin-altitude hypoxia in aircrew not associated with RLS (PMID 31666154).
• 2019-karroum-tox3-painful-rls-variant.md - A TOX3 variant is specifically associated with a painful-RLS sensory subphenotype (PMID 31706190).
• 2019-lyu-btbd9-cerebral-cortex-corticostriatal.md - Cortex-specific Btbd9 knockout alone reproduces motor restlessness and altered corticostriatal plasticity (PMID 31715135).
• 2019-lyu-btbd9-striatum-medium-spiny.md - Striatal medium-spiny-neuron-specific Btbd9 knockout reproduces the full RLS-like phenotype (PMID 31444227).
• 2019-sarayloo-meis1-mineral-absorption-pathway.md - MEIS1 dysregulation enriches a mineral-absorption (HMOX1/VDR) pathway, replicated in postmortem RLS brain (PMID 31725784).
• 2020-sarayloo-skor1-transcriptional-regulation.md - SKOR1 regulates neurodevelopment and iron-metabolism genes; co-represses Lbx1 in dorsal-horn interneuron fate specification (PMID 32572201).
• 2022-lyu-btbd9-purkinje-cell-channels.md - BTBD9 loss alters Purkinje-cell BK/SK potassium channel currents; Purkinje-specific knockout causes motor coordination deficits (PMID 36244636).
• 2022-rodrigues-adenosine-receptor-stoichiometry.md - Brain iron deficiency selectively reduces the A1:A2A adenosine-receptor ratio at cortico-striatal glutamatergic terminals (PMID 35268590).
• 2023-hochstrasser-plms-carotid-thickness.md - PLMS (not RLS diagnosis itself) independently correlates with carotid intima-media thickness (PMID 38524158).
• 2024-kittke-meis1-neural-stem-cell-targets.md - MEIS1 directly regulates three RLS-associated genes (NTNG1, MDGA1, DACH1) in human neural stem cells (PMID 39578497).
• 2024-leu-meis1-patient-variant-mouse.md - A patient-derived MEIS1 missense variant knocked into mice causes age-dependent, rest-phase-specific hyperactivity in aged females (PMID 38314840).
• 2026-franco-exercise-adenosine-dopamine-model.md - Treadmill exercise reverses iron-deficiency-induced sleep impairment and raises DAT/adenosine-A1-receptor expression (PMID 42069295).
• 2026-joo-meis1-zebrafish-cerebellum.md - Zebrafish lacking meis1b show disrupted cerebellar development and disinhibited, ataxia/dystonia-like locomotor output (PMID 42309051).